转移性肾癌的临床治疗进展  

Therapeutic advances in metastatic renal cell carcinoma

作　　者：张金超[1] 王丹红[1] 

机构地区：[1]军事医学科学院附属医院移植科,北京100071

出　　处：《临床泌尿外科杂志》2016年第6期574-579,共6页Journal of Clinical Urology

摘　　要：肾癌是一种免疫原性极强的肿瘤,目前生物治疗已成为转移性肾癌治疗领域的焦点。随着分子靶向药物的出现与发展,转移性肾癌的靶向治疗已逐渐代替了以前单纯的干扰素-α和白细胞介素-2的细胞因子治疗。细胞免疫治疗及免疫检查点抑制剂在肾癌中亦均取得了可靠的疗效证据。本文将对转移性肾癌的免疫治疗和靶向治疗药物作一综述,为临床治疗肾癌提供参考。Renal cell carcinoma（RCC）is a cancer with high immunogenicity,and the biological treatment has become the focus among the treatments of metastatic renal cell carcinoma（MRCC）.With the appearance and development of molecular targeted drugs,the targeted therapy for MRCC has taken the place of the simple cytokine therapy by interferon-αand the interleukin-2.Both the cellular immunotherapy and immune checkpoint inhibitor have gotten credible therapeutic effects.The text will make a review on the immunotherapy and the targeted drugs for MRCC so as to provide clinical references on RCC.

关 键 词：肾癌 分子靶向治疗 免疫治疗 

分 类 号：R737.11[医药卫生—肿瘤]